HUP9901153A2 - Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, előállításuk és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, előállításuk és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9901153A2
HUP9901153A2 HU9901153A HUP9901153A HUP9901153A2 HU P9901153 A2 HUP9901153 A2 HU P9901153A2 HU 9901153 A HU9901153 A HU 9901153A HU P9901153 A HUP9901153 A HU P9901153A HU P9901153 A2 HUP9901153 A2 HU P9901153A2
Authority
HU
Hungary
Prior art keywords
substituted
alkylene
heteroarylalkyl
aryl
alkyl
Prior art date
Application number
HU9901153A
Other languages
English (en)
Inventor
Dashyant Dhanak
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
David Graham Tew
Original Assignee
Smithkline Beecham Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513442.5A external-priority patent/GB9513442D0/en
Priority claimed from GBGB9515056.1A external-priority patent/GB9515056D0/en
Priority claimed from GBGB9515206.2A external-priority patent/GB9515206D0/en
Priority claimed from GBGB9516985.0A external-priority patent/GB9516985D0/en
Priority claimed from GBGB9525132.8A external-priority patent/GB9525132D0/en
Priority claimed from GBGB9608650.9A external-priority patent/GB9608650D0/en
Priority claimed from GBGB9608651.7A external-priority patent/GB9608651D0/en
Application filed by Smithkline Beecham Plc. filed Critical Smithkline Beecham Plc.
Publication of HUP9901153A2 publication Critical patent/HUP9901153A2/hu
Publication of HUP9901153A3 publication Critical patent/HUP9901153A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A találmány szerinti (I) általánős képletű vegyületek (I) - amelyek képletében R1 és R2 egymástól függetlenül hidrőgén-,halőgénatőm vagy alkilcsőpőrt; R4 és R5 egymástól függetlenül hidrőgénatőm, alkil-, alkenil-, aril-,aril-alkil- és heterőaril-alkil-csőpőrt, amelyek mindegyike adőttesetben szűbsztitűált lehet, vagy R4 és R5 a közös szénatőmmal együtt ciklőalkiléncsőpőrtőt képez; X közvetlen kötés, -X1(CH2)m-, amelyben X1 -CO-, -COO-, -CONR6-, -CONR6CO- vagy -CONR6O-, ahől R6 hidrőgénatőmvagy alkilcsőpőrt, és X2 alkiléncsőpőrt, amelyet az alkilénláncőn belül vagy az Yszűbsztitűenssel szőmszédős láncvégen egy vagy több alkenilén- vagyalkiniléncsőpőrt, vagy alkiléncsőpőrttal megszakítőtt lehet, Y adőtt esetben szűbsztitűált arilcsőpőrt; Z őxigénatőm, és R3 alkil-, ciklőalkil-, ciklőalkil-alkil-, heterőaril-, heterőaril-alkil-, aril- vagy aril-alkil-csőpőrt, amelyek mindegyike adőttesetben szűbsztitűált lehet, vagy Z -S(O)n-, amelyben R3 heterőaril- vagy heterőaril-alkil-csőpőrt, amelyek mindegyike adőttesetben szűbsztitűált lehet -, amelyek az Lp PLA2 enzim inhibitőrai. ŕ
HU9901153A 1995-07-01 1996-06-20 Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them HUP9901153A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9513442.5A GB9513442D0 (en) 1995-07-01 1995-07-01 Novel compounds
GBGB9515056.1A GB9515056D0 (en) 1995-07-22 1995-07-22 Novel compounds
GBGB9515206.2A GB9515206D0 (en) 1995-07-25 1995-07-25 Novel compounds
GBGB9516985.0A GB9516985D0 (en) 1995-08-18 1995-08-18 Novel compounds
GBGB9525132.8A GB9525132D0 (en) 1995-12-08 1995-12-08 Novel compounds
GBGB9608650.9A GB9608650D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9608651.7A GB9608651D0 (en) 1996-04-26 1996-04-26 Novel compounds

Publications (2)

Publication Number Publication Date
HUP9901153A2 true HUP9901153A2 (hu) 1999-08-30
HUP9901153A3 HUP9901153A3 (en) 1999-11-29

Family

ID=27562921

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901153A HUP9901153A3 (en) 1995-07-01 1996-06-20 Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them

Country Status (23)

Country Link
EP (1) EP0840725A1 (hu)
JP (1) JP2002515852A (hu)
KR (1) KR19990028630A (hu)
CN (1) CN1197452A (hu)
AP (1) AP728A (hu)
AU (1) AU708032B2 (hu)
BG (1) BG102214A (hu)
BR (1) BR9609445A (hu)
CA (1) CA2225627A1 (hu)
CZ (1) CZ422197A3 (hu)
EA (1) EA199800109A1 (hu)
HU (1) HUP9901153A3 (hu)
IL (1) IL122650A0 (hu)
MA (1) MA23922A1 (hu)
MX (1) MX9800186A (hu)
NO (1) NO976158L (hu)
NZ (1) NZ311684A (hu)
OA (1) OA10648A (hu)
PE (1) PE8998A1 (hu)
PL (1) PL324240A1 (hu)
SK (1) SK178497A3 (hu)
TR (1) TR199701762T1 (hu)
WO (1) WO1997002242A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
BR9709196A (pt) * 1996-04-26 1999-05-25 Smithkline Beecham Plc Derivados de azetidinona para o tratamento de aterosclerose
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
WO2001060805A1 (en) 2000-02-16 2001-08-23 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
KR101461659B1 (ko) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
WO2008141176A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
JP5886310B2 (ja) 2010-12-06 2016-03-16 グラクソ グループ リミテッドGlaxo Group Limited Lp−PLA2により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
CN103619831B (zh) 2011-06-27 2016-05-04 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
BR112014001665A2 (pt) 2011-07-27 2017-02-14 Glaxo Group Ltd compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
RU2014107486A (ru) 2011-07-27 2015-09-10 Глэксо Груп Лимитед Бициклические пиримидоновые соединения
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Lp‐PLA2の阻害剤としての二環式ピリミドン化合物
UY35276A (es) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos que inhiben la actividad de Lp-PLA2
WO2014114248A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
PL320937A1 (en) * 1994-12-22 1997-11-10 Smithkline Beecham Plc Substituted azetidin-2-ones for treating arterial atheromatosis

Also Published As

Publication number Publication date
NO976158L (no) 1998-02-25
SK178497A3 (en) 1998-07-08
JP2002515852A (ja) 2002-05-28
PL324240A1 (en) 1998-05-11
EP0840725A1 (en) 1998-05-13
WO1997002242A1 (en) 1997-01-23
BG102214A (en) 1998-08-31
CN1197452A (zh) 1998-10-28
AU708032B2 (en) 1999-07-29
EA199800109A1 (ru) 1998-10-29
AU6305096A (en) 1997-02-05
HUP9901153A3 (en) 1999-11-29
PE8998A1 (es) 1998-03-20
KR19990028630A (ko) 1999-04-15
CA2225627A1 (en) 1997-01-23
NO976158D0 (no) 1997-12-30
CZ422197A3 (cs) 1998-06-17
BR9609445A (pt) 1999-04-06
IL122650A0 (en) 1998-08-16
TR199701762T1 (xx) 1998-05-21
MA23922A1 (fr) 1996-12-31
AP9701161A0 (en) 1998-01-31
MX9800186A (es) 1998-07-31
OA10648A (en) 2002-09-25
AP728A (en) 1999-01-29
NZ311684A (en) 2000-04-28

Similar Documents

Publication Publication Date Title
HUP9901153A2 (hu) Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, előállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP9801045A2 (hu) Szulfonil-amino-karbonsav-származékok, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP9901752A2 (hu) Rotamáz enzim hatását gátló piperidin-karbonsav-származékok alkalmazása neurológiai aktivitás kezelésére alkalmas gyógyszerkészítmény előállítására
HUP9900790A2 (hu) Imidazo-kinazolin-származékok
HUP0300082A2 (en) 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivatives, process for their preparation and use and pharmaceutical compositions containing them
HUP0004422A2 (hu) 2-Aril-8-oxohidropurin-származékok, eljárás előállításukra, ilyen vegyületeket tartalmazó gyógyászati készítmények
NO994452D0 (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
HUP0300618A2 (hu) Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0302153A2 (hu) Kemokin receptor aktívitás modulátoraiként hatásos piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0000965A2 (hu) Foszfolipáz A2 inhibitor hatású pirrolidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
WO2004085421A3 (en) Bioreductively-activated prodrugs
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP9801599A2 (hu) Alfa1L-agonista imidazolinszármazékok alkalmazása inkontinencia kezelésére szolgáló gyógyszerkészítmények előállítására, új imidazolin-származékok és eljárás ezek előállítására
TR200102957T2 (tr) Sitalopram hazırlanması için metod.
HUP9904147A2 (hu) Vízoldható kopolimerek alkalmazása aktív alkotórészként kozmetikai készítményekben
NZ503076A (en) 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives and addition salts thereof, with antagonism against amino acid receptors (particularly AMPA receptor) and processes for their preparation
HUP9904682A2 (hu) Fenil-oxazol- és -tiazol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP9903808A2 (hu) Eljárás szubsztituált aril-tejsavat tartalmazó 24 gyűrűatomos ciklodepszipeptidek előállítására
HUP9800051A2 (hu) 1-Aril-2-acil-amino-etán-vegyületek, alkalmazásuk neurokinin-antagonista gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9801766A2 (hu) 6-Karboxamido-dihidropirán-származékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
HUP0000894A2 (hu) Szubsztituált (1,3-bisz(ciklohexilmetil)-1,2,3,6-tetrahidro-2,6-dioxo-9H-purin-8-il)fenil-származékok és eljárás előállításukra
HUP9802143A2 (hu) 5-Tagú heterociklusos vegyületek, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények
NZ314406A (en) Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
HUP9801057A2 (hu) Piridil-tiazol-származékok és mikroorganizmusok elleni növényvédő szerként történő alkalmazásuk
HUP9802042A2 (hu) Taxoidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények